Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
1.275
-0.005 (-0.39%)
Mar 31, 2025, 1:15 PM EDT - Market open
Company Description
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Climb Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Aoife Brennan |
Contact Details
Address: PMB #117, 2801 Centerville Road, 1st Floor Wilmington, Delaware 19808-1609 United States | |
| Phone | 866 857 2596 |
| Website | eliemtx.com |
Stock Details
| Ticker Symbol | CLYM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001768446 |
| ISIN Number | US28658R1068 |
| Employer ID | 83-2273741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President and Director |
| Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer and Principal Financial Officer |
| Emily Pimblett CPA | Senior Vice President of Finance and Chief Accounting Officer |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development |
| Janaki M. Subramanyam M.Sc. | Vice President and Head of Regulatory Affairs |
| Kate Hecht M.B.A. | Senior Vice President of Program Management |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 424B5 | Filing |
| Mar 25, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Nov 22, 2024 | EFFECT | Notice of Effectiveness |
| Nov 19, 2024 | UPLOAD | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 12, 2024 | 8-K | Current Report |